Karyopharm Files Chapter 11 and Names Ayrmid Lead Bidder

Direct event-specific context supports a November 2, 2026 voluntary Chapter 11 filing, a restructuring support agreement contemplating Ayrmid’s merger with reorganized Karyopharm, Ayrmid’s lead-bidder role, competing bids, and up to $55 million of debtor-in-possession financing pending court approval. I retain merger_acquisition because the central forward-looking development is a proposed distressed sale/merger at an announced transaction stage; the DIP financing is supporting liquidity detail rather than the primary classification. Importance is high because this is a major company-specific catalyst, while surprise is moderated by Karyopharm’s prior missed payment and creditor forbearance. Confidence in the core facts is high, but the exact action time is not disclosed, so the timestamp is a date-level estimate at 00:00 UTC. The development is distinct from, but clearly continues, Event 4599. KPTI is directly affected; PFE is approved because the supplied context identifies it as the global commercial-rights licensee for Karyopharm’s product, creating a plausible exposure to the sale process. Other competitors and distributors are excluded because their impacts are too indirect and speculative.